Canji Inc.

Paxvax, Inc.

Timothy P Mayall

Jeff Alexander

The present invention provides replication competent adenoviral vectors capable of expressing antigens from infectious pathogens, such as influenza virus. The adenoviral vectors can be used to vaccinate subjects against the infectious pathogens. The adenoviral vectors comprise heterologous sequences encoding the antigens. The heterologous sequences can be inserted into various locations in the adenoviral vectors, including in or near specific E3 deletions and/or integrated into the adenoviral hexon coding region. The adenoviral vectors can be derived from any adenoviral serotype, particularly an Ad4 or Ad7 serotype.

Adenoviral-based vectors

The present invention provides a recombinant adenovirus vector characterized by the partial or total deletion of adenoviral E2B function and having an expression cassette containing a heterologous sequence encoding a protein of interest inserted into the E1 region. Such vectors are designed to reduce or eliminate the occurrence of replication competent adenovirus contamination. Additionally, the expression cassette of the vector may contain one or more regulatory elements capable of increasing the expression of the heterologous sequence and/or reducing the expression of viral proteins. Such a reduction in expression of viral proteins reduces the cytotoxicty and immunogenicity of the adenovirus vectors when administered in vivo. Transformed production host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention.

Adenoviral expression vectors

Rat secreted embryonic alkaline phosphatase and methods for it use are provided.

Growing community of inventors

Encinitas, CA, United States of America

Timothy P Mayall